Viiv Healthcare, the venture launched last year by GlaxoSmithKline and Pfizer to combine their HIV/AIDS portfolios, will make the intellectual property for the entire portfolio available to generic drug makers in 60 low-income countries. The initiative potentially will make generic versions of drugs like Pfizer's Selzentry (maraviroc) available to 80 percent of all people currently living with HIV.
Germany’s impending health care reform and its specific focus on making savings in the pharmaceutical sector represent a significant threat to the country’s parallel trade sector, as well as wholesaler margins.
Amidst policy debates about Project BioShield, two companies with vaccines funded via the program – Emergent BioSolutions and Bavarian Nordic – announce positive developments.
Biopharma financings roundup: Is venture capital's glass half-full or half-empty?
NICE’s final appraisal determination on Sanofi-Aventis’s Multaq recommends limited use in UK atrial fibrillation patients.
